Stock Analysis on Net
Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Eli Lilly & Co., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Short-term borrowings and current maturities of long-term debt 10.79 3.88 1.21 0.01 3.03 3.68 4.51 2.89 3.15 3.24 3.72 0.01 0.02 1.34 3.01 7.90 3.82 4.13 5.35 6.20
Accounts payable 4.06 4.20 4.51 3.79 3.90 3.55 3.53 3.05 3.42 3.25 3.34 3.50 3.45 3.25 2.97 2.94 3.58 2.94 3.10 3.07
Employee compensation 2.58 2.13 1.58 1.39 2.14 2.07 1.78 1.48 1.96 1.74 1.58 1.39 2.14 1.81 1.61 1.38 2.33 1.86 1.52 1.35
Sales rebates and discounts 18.26 19.90 18.95 17.93 17.75 18.05 16.98 14.43 14.03 14.91 14.72 12.43 12.55 13.07 12.59 11.44 12.56 13.93 12.91 11.72
Dividends payable 1.83 0.00 1.85 0.00 2.06 0.00 1.87 0.00 1.81 0.00 1.61 0.00 1.65 0.00 0.00 0.00 1.71 0.00 1.54 0.00
Other current liabilities 5.13 7.88 6.40 7.00 5.75 5.63 4.53 6.68 6.46 5.25 6.60 7.68 6.96 7.78 8.39 7.02 5.98 5.72 6.24 7.22
Current liabilities 42.64% 37.98% 34.51% 30.11% 34.63% 32.98% 33.19% 28.53% 30.84% 28.39% 31.57% 25.01% 26.77% 27.25% 28.57% 30.68% 29.97% 28.58% 30.66% 29.56%
Long-term debt, excluding current maturities 28.62 30.95 33.13 35.51 29.78 29.80 31.22 32.30 31.44 32.21 30.82 34.59 35.57 37.17 35.90 34.02 35.17 36.05 35.48 35.81
Accrued retirement benefits 2.25 2.27 2.39 2.47 2.64 3.86 4.01 4.14 4.00 8.05 8.20 8.48 8.78 7.82 8.10 8.84 9.41 6.37 7.04 7.26
Long-term income taxes payable 6.01 5.99 6.08 7.23 7.50 7.67 7.56 8.48 8.03 7.82 7.82 8.36 8.23 7.72 8.05 8.81 9.18 9.31 9.01 9.89
Other noncurrent liabilities 3.50 3.29 3.56 3.43 3.69 4.27 5.62 6.39 6.92 7.02 7.65 8.41 8.16 8.67 9.21 9.88 9.39 10.55 10.41 10.73
Other liabilities 40.39% 42.49% 45.15% 48.64% 43.60% 45.60% 48.41% 51.30% 50.40% 55.10% 54.49% 59.83% 60.74% 61.38% 61.25% 61.54% 63.16% 62.29% 61.95% 63.69%
Total liabilities 83.03% 80.48% 79.66% 78.75% 78.23% 78.58% 81.60% 79.83% 81.24% 83.49% 86.06% 84.84% 87.51% 88.63% 89.82% 92.22% 93.13% 90.86% 92.61% 93.25%
Common stock 0.93 1.02 1.08 1.12 1.20 1.25 1.26 1.27 1.22 1.24 1.25 1.28 1.28 1.36 1.43 1.46 1.52 1.58 1.56 1.60
Additional paid-in capital 11.33 12.36 12.68 12.78 13.99 14.39 14.33 14.19 14.00 14.02 13.95 14.05 14.54 15.24 15.80 15.95 17.02 17.44 16.90 15.15
Retained earnings 16.11 17.80 18.92 20.01 20.29 21.08 18.18 19.97 18.36 20.00 17.84 19.60 16.79 16.28 15.77 14.30 12.52 13.15 11.17 12.84
Employee benefit trust -4.71 -5.20 -5.50 -5.67 -6.09 -6.35 -6.40 -6.42 -6.17 -6.25 -6.30 -6.43 -6.46 -6.86 -7.18 -7.33 -7.67 -7.95 -7.79 -7.93
Accumulated other comprehensive loss -6.76 -6.54 -6.91 -7.11 -7.77 -9.05 -9.11 -9.01 -8.90 -12.81 -13.15 -13.65 -13.93 -14.92 -15.92 -16.75 -16.61 -15.13 -14.48 -14.96
Cost of common stock in treasury -0.07 -0.08 -0.08 -0.08 -0.10 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.11 -0.12 -0.13 -0.13 -0.14 -0.15 -0.16 -0.16 -0.16
Total Eli Lilly and Company shareholders’ equity 16.83% 19.37% 20.18% 21.05% 21.52% 21.22% 18.16% 19.89% 18.40% 16.10% 13.48% 14.73% 12.10% 10.98% 9.75% 7.49% 6.64% 8.93% 7.19% 6.53%
Noncontrolling interests 0.14 0.15 0.16 0.20 0.25 0.20 0.24 0.28 0.36 0.41 0.46 0.43 0.39 0.38 0.43 0.29 0.23 0.21 0.20 0.22
Total equity 16.97% 19.52% 20.34% 21.25% 21.77% 21.42% 18.40% 20.17% 18.76% 16.51% 13.94% 15.16% 12.49% 11.37% 10.18% 7.78% 6.87% 9.14% 7.39% 6.75%
Total liabilities and equity 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Eli Lilly & Co. current liabilities as a percentage of total liabilities and equity increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Other liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Eli Lilly & Co. other liabilities as a percentage of total liabilities and equity decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Eli Lilly & Co. total liabilities as a percentage of total liabilities and equity increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Total Eli Lilly and Company shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Eli Lilly & Co. total Eli Lilly and Company shareholders’ equity as a percentage of total liabilities and equity decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.